Recently, China’s National Medical Products Administration (NMPA) officially granted a Class III medical device registration certificate to an invasive brain–computer interface (BCI) product Neurestora for the treatment of substance addiction.
This approval marks China’s first invasive BCI product for the treatment of addiction-related psychiatric disorders, and the world’s first of its kind, signaling China’s global leadership in the application of brain–computer interface technology for addiction treatment.
As a representative enterprise in China’s brain–computer interface sector, SeneRay is committed to achieving groundbreaking innovations from zero to one in BCI technology. The company aims to help more patients with psychiatric and neurological disorders return to normal life, becoming a beacon of hope that illuminates the inner world of those suffering from brain function–related diseases.
